Topic : Medications Featured

Other Topics :

How well do people do in the real world?

Much of what we know about the long-term outcomes of people with chronic myelogenous leukemia comes from clinical studies. Such studies provide important information about how well a person with CML can do over the longer term. But one of their limitations is that studies are selectiv
Continue Reading →

Surviving CML – What about the year to come?

It’s well known that the introduction of tyrosine kinase inhibitors (TKIs, such as Gleevec, Sprycel, Tasigna and Bosulif) have significantly prolonged survival in people with chronic myelogenous leukemia. Where once a CML diagnosis meant an expected survival of only a few years, survi
Continue Reading →

Evaluating high-dose Gleevec

Before the second-generation TKIs (Sprycel, Tasigna, Bosulif) became available, the best option for people with an inadequate response to Gleevec was to give more Gleevec. So many studies used twice the usual dose (or 800 mg per day).
Continue Reading →

Most people will achieve treatment response targets

A new study has looked at the proportion of people with CML who achieve the key treatment milestones, which represent the optimal response to a medication at different time points (Jain and colleagues. Br J Haematol 2016;173:114-126). These milestones are developed by research groups
Continue Reading →

Generic imatinib: patient advocacy groups’ recommendations

Gleevec has been the cornerstone of CML treatment for the past 15 years. However, the introduction of a generic formulation (imatinib) has made patients and physicians uncertain about the medications that are being used, according to The CML Advocates Network, a network of CML patient
Continue Reading →

“Deep molecular response” – how an idea evolved

TKI (tyrosine kinase inhibitor) therapy established a new standard for what medications could achieve in the treatment of CML (and set the bar for all cancer therapies). With TKIs, the goal posts shifted, but what constitutes a success has continued to evolve over time. The most recen
Continue Reading →

6 Key Questions about CML Treatment

After being diagnosed with chronic myelogenous leukemia, you and your doctor will need to make some decisions about the treatments you’ll need to keep your disease under control. The following are some of the most important questions about CML medications and how medical research has
Continue Reading →

What if treatment doesn’t work?

The development of Gleevec in 2001 revolutionized the treatment of CML. But the medication – although highly effective – won’t work in everyone, and some people may develop resistance to the drug. One reason for resistance is mutations, and over 80 different mutations have now been de
Continue Reading →

Is a drug holiday ever possible?

A great deal of attention has been paid to “treatment-free remission” (TFR), where people who have been stable on treatment for many years are able to stop taking their TKI medication.
Continue Reading →

ASCO 2014 – Overview of recent drug studies

The results from several important treatment studies were presented at this year’s ASCO meeting. Here is a brief summary of the results.
Continue Reading →